Lysophosphatidylcholines belong to a group of lipid components which have a variety of physiological functions. LPCs are known to be linked to metabolic disorders and cardio-vascular diseases,including diabetes,atherosclerosis and dyslip-idemia.LPCs are actively metabolized in liver,which is closely related with liver diseases and hepatotoxicity.The role of LPCs in liver diseases and hepatotoxicities has been extensively investi-gated recently.This review focuses on lysophosphatidylcholines as a biomarker for liver diseases,such as hepatic carcinoma, cholestasis,cirrhosis,hepatitis,and chemical hepatotoxicities, trying to lay a basis for investigation and therapeutics of liver dis-eases.

Objective:To provide a preliminary theoretical basis for gout and hyperuricemia of Deoxyribonucleic acid (DNA) methylation.Methods:Breast cancer anti-resistance 1(BCAR1), phospho-diesterase 1C (PDE1C), opioid receptor delta 1(OPRD1) and neurexin 1(NRXN1) methylation levels were measured by bisulfite pyrosequencing in 50 gout patients, 30 hyperuricemia patients and 50 matched healthy controls. Comparisons between groups were evaluated by F-test and Nonparametric tests. Results:Receiver operating characteristic showed that the methylation of PDE1C(pos4, pos5, pos6)(AUC: 0.712, 0.772, 0.775; all P values<0.05) had higher accuracy for diagnosis of gout, and OPRD1 pos4 (AUC=0.733, P<0.05) had higher accuracy for hyperuricemia. Conclusion:DNA methylation may play a role in the development of gout and hyperuricemia, however, further studies are needed.